Amphastar Pharmaceuticals (AMPH) investor relations material

Business overview and strategy

• Operates as a fully integrated pharmaceutical company with in-house product development, manufacturing, and distribution, primarily in the U.S. but with global reach.

• Focuses on high quality, efficiency, and technology, resulting in net income margins rising from the teens to the 20s as product mix expanded.

• Transitioned pipeline from mostly complex generics to a majority proprietary and biosimilar focus, aiming for 50% proprietary, 35% biosimilars, and 15% generics by year-end.

• Invests heavily in R&D, with expenses rising to 11.9% of revenue and expected to increase further as proprietary products grow.

• Maintains a diversified and scalable pipeline, leveraging vertical integration for flexibility in sourcing and research.

Product and pipeline highlights

• Proprietary pipeline includes AMP-101 (intranasal epinephrine for anaphylaxis, in phase I), AMP-105/107/109 (oncology and ophthalmology peptides, in preclinical U.S. studies), and AMP-110 (synthetic corticotropin targeting a $1B market).

• AMP-109 shows strong anti-tumor activity in pancreatic cancer mouse models, with high-dose treatment eliminating tumors in most cases.

• BAQSIMI, an intranasal glucagon for hypoglycemia, was acquired and is now sold in 26 countries, with projected peak annual sales of $250–$275 million.

• Primatene MIST, the only FDA-approved OTC asthma inhaler, is patent-protected and undergoing further green formulation development.

• Launched new generics and biosimilars, including teriparatide (AMP-015), ipratropium bromide, and upcoming GLP-1 and insulin biosimilars targeting large markets.

Financial performance and capital structure

• Revenue has grown from $210 million at IPO in 2014 to an expected $700–$750 million this year, with significant diversification away from reliance on a single product.

• R&D is funded by strong cash flow from a broad product base, with $285 million in cash, $200 million undrawn revolver, and $200+ million annual EBITDA.

• Current debt totals $600 million, but management is confident in refinancing and paying down debt as needed, supported by future cash generation.

• Capital structure is sufficient to fund all R&D projects through phase II over the next five years.